Viridian legal chief sells 14,212 shares at $24.50

Viridian Therapeutics, Inc. (VRDN) reported that Chief Legal Officer Jennifer Tousignant exercised stock options and sold shares on August 19, 2026.

Rhea-AI Filing Summary

Viridian Therapeutics, Inc. (VRDN) reported that Chief Legal Officer Jennifer Tousignant exercised stock options and sold shares on August 19, 2026. She exercised options to acquire 10,000 shares of common stock at $14.41 per share, then sold a total of 14,212 shares of common stock at $24.50 per share in open-market or private transactions, including 718 shares previously acquired under the company’s Employee Stock Purchase Plan. Following the option exercise, 114,072 option shares remain outstanding under the reported grant, which was issued on March 3, 2025 and vests in 48 equal monthly installments through March 3, 2029, with an expiration date of March 3, 2035.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 4 txns

Insider Tousignant Jennifer

Role Chief Legal Officer

Sold 14,212 shs ($348K)

Approx. gross sale proceeds $348K

Approx. exercise cost $144K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy) F2	10,000	$0.00	$0.00
Sale	Common Stock F1	4,212	$24.50	$103K
Exercise	Common Stock	10,000	$14.41	$144K
Sale	Common Stock	10,000	$24.50	$245K

Holdings After Transaction: Stock Option (Right to Buy) — 114,072 contracts (Direct); Common Stock — 0 shares (Direct)

Footnotes (2)

1. F1. The shares sold include 718 shares previously acquired by the reporting person pursuant to the Viridian Therapeutics, Inc. Employee Stock Purchase Plan in a transaction that was exempt under Rule 16b-3(c).
2. F2. The option was granted on March 3, 2025 and vests in 48 equal monthly installments following the date of the grant, subject to the Reporting Person's continued service to Issuer through each vesting date.

Key Figures

Option shares exercised: 10,000 shares Exercise price: $14.41 per share Shares sold: 14,212 shares +5 more

8 metrics

Option shares exercised 10,000 shares Stock option exercise on 2026-08-19

Exercise price $14.41 per share Exercise or conversion of derivative security

Shares sold 14,212 shares Common stock sales on 2026-08-19

Sale price $24.50 per share Sale in open market or private transaction

Option shares remaining 114,072 shares Derivative securities beneficially owned following transaction

ESPP shares included in sale 718 shares Previously acquired under Employee Stock Purchase Plan

Option vesting period 48 equal monthly installments Vesting following March 3, 2025 grant date

Option expiration date March 3, 2035 Expiration of reported stock option

Key Terms

Stock Option (Right to Buy), Employee Stock Purchase Plan, Rule 16b-3(c)

3 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

Employee Stock Purchase Plan financial

"acquired by the reporting person pursuant to the Viridian Therapeutics, Inc. Employee Stock Purchase Plan"

An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.

Rule 16b-3(c) regulatory

"in a transaction that was exempt under Rule 16b-3(c)"

An SEC rule that lets corporate insiders avoid automatic "short‑swing" profit recovery when they buy or sell their company’s stock under a pre‑approved, written plan that meets specific conditions. For investors, it matters because it clarifies when insider trades are treated as routine, reducing legal uncertainty and helping distinguish trades made for ordinary compensation or pre‑planned reasons from those that might signal opportunistic or timely insider advantage.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did VRDN’s Chief Legal Officer report on this Form 4?

Jennifer Tousignant exercised stock options for 10,000 shares of Viridian Therapeutics, Inc. common stock at $14.41 per share and sold a total of 14,212 shares at $24.50 per share in open-market or private transactions on August 19, 2026.

How many VRDN shares did the insider sell and at what price?

On August 19, 2026, the reporting person sold an aggregate of 14,212 shares of Viridian Therapeutics, Inc. common stock at a price of $24.50 per share, in sales reported as open-market or private transactions.

What stock options did the VRDN insider exercise in this filing?

The reporting person exercised a stock option covering 10,000 shares of Viridian Therapeutics, Inc. common stock at an exercise price of $14.41 per share, described as an exercise or conversion of a derivative security.

How many option shares remain for the VRDN insider after these transactions?

After the reported option exercise, the filing shows the reporting person holding 114,072 option shares under the referenced stock option, as indicated by the total derivative securities beneficially owned following the transaction.

What are the vesting and expiration terms of the VRDN stock option in this Form 4?

The option was granted on March 3, 2025 and vests in 48 equal monthly installments following the grant date, subject to continued service. The option has an expiration date of March 3, 2035.

Were any VRDN Employee Stock Purchase Plan shares included in the sale?

Yes. The filing notes that the 14,212 shares sold include 718 shares previously acquired under the Viridian Therapeutics, Inc. Employee Stock Purchase Plan in a transaction that was exempt under Rule 16b-3(c).

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/20/2026 - 08:05 PM Accepted by SEC EDGAR 08/20/2026 - 08:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tousignant Jennifer

(Last) (First) (Middle)

C/O VIRIDIAN THERAPEUTICS, INC.

221 CRESCENT STREET, SUITE 103A

(Street)

WALTHAM MASSACHUSETTS 02453

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Viridian Therapeutics, Inc.\DE [ VRDN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/19/2026		S		4,212(1)	D	$24.5	0	D
Common Stock	08/19/2026		M		10,000	A	$14.41	10,000	D
Common Stock	08/19/2026		S		10,000	D	$24.5	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$14.41	08/19/2026		M			10,000	(2)	03/03/2035	Common Stock	10,000	$0.00	114,072	D

Explanation of Responses:

1. The shares sold include 718 shares previously acquired by the reporting person pursuant to the Viridian Therapeutics, Inc. Employee Stock Purchase Plan in a transaction that was exempt under Rule 16b-3(c).

2. The option was granted on March 3, 2025 and vests in 48 equal monthly installments following the date of the grant, subject to the Reporting Person's continued service to Issuer through each vesting date.

	/s/ Jennifer Tousignant	08/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)